PNC Financial Services Group Inc. Sells 15,439 Shares of Edwards Lifesciences Corporation $EW

PNC Financial Services Group Inc. lessened its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 2.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 551,048 shares of the medical research company’s stock after selling 15,439 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Edwards Lifesciences were worth $42,855,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Brighton Jones LLC bought a new position in Edwards Lifesciences in the 4th quarter worth $266,000. Ritholtz Wealth Management acquired a new position in shares of Edwards Lifesciences in the 2nd quarter worth approximately $203,000. Private Trust Co. NA lifted its position in shares of Edwards Lifesciences by 9.6% during the 2nd quarter. Private Trust Co. NA now owns 4,346 shares of the medical research company’s stock worth $340,000 after buying an additional 380 shares during the period. Chicago Partners Investment Group LLC boosted its stake in Edwards Lifesciences by 12.9% in the 2nd quarter. Chicago Partners Investment Group LLC now owns 7,479 shares of the medical research company’s stock valued at $575,000 after buying an additional 854 shares in the last quarter. Finally, Evermay Wealth Management LLC grew its holdings in shares of Edwards Lifesciences by 5.5% in the 2nd quarter. Evermay Wealth Management LLC now owns 2,983 shares of the medical research company’s stock worth $233,000 after purchasing an additional 156 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Evercore reaffirmed an “outperform” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a report on Monday, January 5th. JPMorgan Chase & Co. upgraded shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $90.00 to $100.00 in a research report on Thursday, December 18th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, January 21st. The Goldman Sachs Group reissued a “buy” rating and set a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Finally, Stifel Nicolaus set a $110.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Tuesday, January 20th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $96.14.

Insider Buying and Selling at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 7,700 shares of Edwards Lifesciences stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total transaction of $650,419.00. Following the transaction, the chief financial officer owned 39,898 shares in the company, valued at $3,370,184.06. The trade was a 16.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of the stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $83.76, for a total value of $953,691.36. Following the sale, the vice president directly owned 38,970 shares of the company’s stock, valued at approximately $3,264,127.20. The trade was a 22.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 43,804 shares of company stock valued at $3,699,082. Company insiders own 0.34% of the company’s stock.

Edwards Lifesciences Stock Down 0.8%

Shares of NYSE:EW opened at $75.80 on Tuesday. Edwards Lifesciences Corporation has a 52 week low of $65.94 and a 52 week high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The company has a market capitalization of $43.99 billion, a PE ratio of 41.42, a PEG ratio of 1.99 and a beta of 0.94. The company has a 50 day moving average price of $83.17 and a two-hundred day moving average price of $81.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The firm had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same period in the prior year, the business earned $0.59 earnings per share. The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.